InvestorsHub Logo
Followers 20
Posts 2280
Boards Moderated 0
Alias Born 05/04/2005

Re: None

Friday, 04/01/2022 2:40:22 AM

Friday, April 01, 2022 2:40:22 AM

Post# of 811
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on VYNE Therapeutics (VYNE – Research Report) and Ocuphire Pharma (OCUP – Research Report) with bullish sentiments. VYNE Therapeutics (VYNE) H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on VYNE Therapeutics yesterday and set a price target of $7.00. The company's shares closed last Wednesday at $0.73, close to its 52-week low of $0.46. According to TipRanks.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VYNE News